| Mgmt Confidence | Enthusiastic about clinical data but cautious, citing capital as restriction on speed. |
|---|---|
| Demand Visibility | High investigator interest; 32 sites with contracts, 30 more in negotiation. |
| Segment Growth | Invincible 3 (Sarcoma) and Invincible 4 (Breast Cancer) both resumed enrollment Q3. |
| New Clients | Added new CROs for statistical analysis and central CT image reading. |
| Capex & Debt | Raised $3.2M via ATM; $8.5M cash; $1M monthly burn expected Q4. |
| Regulatory | Switching to Choi density criteria for Phase 3; IDMB safety review Q1. |
| Commentary | Management argues water-based drugs fail in tumors; their product is lipid-compatible. |
| New Launches | Initiated new manufacturing batch of INT230-6; completion expected Q1 2027. |
Growth
Net loss increased 33% to $3.5 million; R&D expenses rose 56% to $2.4 million.
Outlook
Targeting completion of Invincible 4 enrollment by end of 2027, pending incremental funding.
Risks
Management pivoted on specific enrollment numbers, admitting capital is the primary gating factor for speed.
The company's earnings call, NASDAQ: INTS, and its 8-K filed with the SEC. Summary written with AI assistance from the call.
Earnings call webcast ↗ Watch on YouTube ↗
Intensity Therapeutics, Inc.: key numbers
- Share price
- $3.07Close, Nov 16
- Market cap
- $10.1M
- Shares outstanding
- 3.3MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Biological Products, (No Diagnostic Substances)SIC 2836
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Intensity Therapeutics, Inc.
All →Intensity Therapeutics Business Update
Intensity Therapeutics reported its Q3 2026 financial results and provided an operational update on its clinical pipeline, including the resumption of patient enrollment in the Phase 3 INVINCIBLE-3 soft tissue sarcoma study and the Phase 2 INVINCIBLE-4 triple-negative breast cancer study. The company ended the quarter with $8.5 million in cash and cash equivalents.
Intensity Therapeutics Q3 2026 Results: Net Loss of $3.54M, Loss Widens
Intensity Therapeutics reported a net loss of $9.0 million for the nine months ended September 30, 2026, compared to $8.6 million in the prior year period. The company's cash position decreased to $8.5 million from $11.9 million at year-end 2025, primarily due to ongoing research and development expenses for its lead drug candidate, INT230-6.
- Key figure
- Net loss $3.54M